Novo Nordisk (NVO)
(Delayed Data from NYSE)
$111.95 USD
-1.29 (-1.14%)
Updated Oct 31, 2024 04:00 PM ET
After-Market: $111.90 -0.05 (-0.04%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth A Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
NVO 111.95 -1.29(-1.14%)
Will NVO be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for NVO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NVO
Amgen Q3 Earnings Beat, Sales In Line, Obesity Candidate in Focus
Lilly's Q3 Earnings Miss, Mounjaro, Zepbound Disappoint, Stock Tanks
NVO: What are Zacks experts saying now?
Zacks Private Portfolio Services
The Zacks Analyst Blog Apple, Novo Nordisk, RTX and FONAR
Top Research Reports for Apple, Novo Nordisk & RTX
Can Mounjaro, Zepbound Help Eli Lilly Top Earnings Estimates Again?
Other News for NVO
Wegovy and Ozempic Gain Full Availability in U.S.
Microsoft reports Q1 beat, Comcast weighs cable networks spinoff: Morning Buzz
Microsoft reports Q1 beat, Comcast weighs cable networks spinoff: Morning Buzz
Deutsche Bank Sticks to Its Buy Rating for Novo Nordisk (0QIU)
Novo’s Ozempic, Wegovy listed as available by FDA, STAT reports